Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | PPARG | P37231 | 6/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.61 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.61 |
| ▸ | RXRA | P19793 | 2/20 | 0.61 |
| ▸ | CNR1 | P21554 | 4/20 | 0.57 |
| ▸ | CNR2 | P34972 | 4/20 | 0.57 |
| ▸ | F7 | P08709 | 4/20 | 0.49 |
| ▸ | F3 | P13726 | 4/20 | 0.49 |
| ▸ | PPARD | Q03181 | 4/20 | 0.49 |
| ▸ | PPARA | Q07869 | 4/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16450794 | 1.00 | MAPT (0.67) | MAPTALDH1A1PPARGCYP19A1FFAR1 | |
| SCHEMBL22451075 | 0.94 | ALDH1A1 (0.71) | MAPTALDH1A1PPARGCYP19A1FFAR1 | |
| SCHEMBL3407185 | 0.94 | ALDH1A1 (0.71) | MAPTALDH1A1PPARGCYP19A1FFAR1 | |
| SCHEMBL3408523 | 0.94 | ALDH1A1 (0.71) | MAPTALDH1A1PPARGCYP19A1FFAR1 | |
| SCHEMBL15335275 | 0.94 | ALDH1A1 (0.71) | MAPTALDH1A1PPARGCYP19A1FFAR1 | |
| SCHEMBL3407181 | 0.94 | ALDH1A1 (0.71) | MAPTALDH1A1PPARGCYP19A1FFAR1 | |
| SCHEMBL15335274 | 0.91 | MAPT (0.81) | MAPTALDH1A1PPARGCYP19A1FFAR1 | |
| SCHEMBL31570910 | 0.91 | MAPT (0.81) | MAPTALDH1A1PPARGCYP19A1FFAR1 | |
| SCHEMBL29922202 | 0.91 | MAPT (0.81) | MAPTALDH1A1PPARGCYP19A1FFAR1 | |
| SCHEMBL655399 | 0.91 | MAPT (0.81) | MAPTALDH1A1PPARGCYP19A1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687496-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) | 2026-02-11 | — | — | EP | claimed |
| US-20250216407-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. | 2025-07-03 | — | — | US | claimed |
| WO-2024200855-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO Y POLITECNICO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2024-10-03 | — | — | WO | claimed |
| EP-4437858-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) | 2024-10-02 | — | — | EP | claimed |
| US-11865096-B2 | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors | SOLUTEX NA LLC | 2024-01-09 | — | — | US | claimed |
| EP-2858496-B9 | OILS WITH ANTI-INFLAMMATORY ACTIVITY CONTAINING NATURAL SPECIALIZED PRORESOLVING MEDIATORS AND THEIR PRECURSORS | SOLUTEX NA LLC (US) | 2023-11-29 | — | — | EP | claimed |
| WO-2023192314-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| US-20230284643-A1 | MILK PRODUCT COMPOSITIONS | BIOMILQ INC (US) | 2023-09-14 | — | — | US | claimed |
| EP-4205546-A1 | OILS WITH ANTI-INFLAMMATORY ACTIVITY CONTAINING NATURAL SPECIALIZED PRORESOLVING MEDIATORS AND THEIR PRECURSORS | Solutex NA LLC (US) | 2023-07-05 | — | — | EP | claimed |
| EP-2858496-B1 | OILS WITH ANTI-INFLAMMATORY ACTIVITY CONTAINING NATURAL SPECIALIZED PRORESOLVING MEDIATORS AND THEIR PRECURSORS | SOLUTEX NA LLC (US) | 2023-04-12 | — | — | EP | claimed |
| EP-4157990-A1 | MILK PRODUCT COMPOSITIONS | Biomilq, Inc. (US) | 2023-04-05 | — | — | EP | claimed |
| US-20220175711-A1 | OILS WITH ANTI-INFLAMMATORY ACTIVITY CONTAINING NATURAL SPECIALIZED PRORESOLVING MEDIATORS AND THEIR PRECURSORS | SOLUTEX NA LLC | 2022-06-09 | — | — | US | claimed |
| US-11285126-B2 | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors | SOLUTEX NA LLC (US) | 2022-03-29 | — | — | US | claimed |
| US-20200316086-A1 | COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS, 17-HDHA AND 18-HEPE AND METHODS OF USING SAME | SOLUTEX NA LLC | 2020-10-08 | — | — | US | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-12590320-B2 | Cellular models of and therapies for ocular diseases | REFLECTION BIOTECHNOLOGIES LIMITED (HK) | 2026-03-31 | — | — | US | disclosed |
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2007127377-A2 | COMBINATIONS COMPRISING OMEGA-3 FATTY ACID COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | ALOX15B, ALOX5, ALOX15 | MAPT 4520/4885ALDH1A1 1517/4885PPARG 138/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | MAPT 2450/4885ALDH1A1 756/4885PPARG 11/4885 |
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | ALOX5, ALOX15, ALOX15B | MAPT 2662/4885ALDH1A1 2772/4885PPARG 202/4885 |
| US-12590320-B2 | Cellular models of and therapies for ocular diseases | ALDH1A2, NR2E3, RBP4 | MAPT 981/4885ALDH1A1 1965/4885PPARG 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.